How does deucravacitinib fit into the treatment landscape for plaque psoriasis?

The Psoriasis and Psoriatic Arthritis Hub was pleased to speak with Paolo Gisondi, University Hospital of Verona, Verona, IT. We asked, How does deucravacitinib fit into the treatment landscape for plaque psoriasis? 

Gisondi discusses the benefit of oral therapies, such as deucravacitinib, as a more convenient and patient-friendly treatment option than injectable treatments. He highlights that injectable therapies can be intimidating for patients who are starting a new systemic treatment, then goes on to discuss the efficacy and, in particular, the safety benefit of deucravacitinib due to its allosteric inhibition of tyrosine kinase 2 (TYK2), when compared with Janus kinase (JAK) inhibitors. He emphasizes the reduced risk of infections, such as upper respiratory tract infections or nasopharyngitis, in patients treated with deucravacitinib vs JAK inhibitors. Finally, he discusses the potential of deucravacitinib in patients with psoriasis with characteristics of eczema, and in patients who had paradoxical eczema reactions to interleukin-17 (IL-17) inhibitors.  

This educational resource is independently supported by Bristol Myers Squibb. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.